1
|
Conforti F, Davies ER, Calderwood CJ, Thatcher TH, Jones MG, Smart DE, Mahajan S, Alzetani A, Havelock T, Maher TM, Molyneaux PL, Thorley AJ, Tetley TD, Warner JA, Packham G, Ganesan A, Skipp PJ, Marshall BJ, Richeldi L, Sime PJ, O'Reilly KMA, Davies DE. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget 2018; 8:48737-48754. [PMID: 28467787 PMCID: PMC5564721 DOI: 10.18632/oncotarget.17114] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Accepted: 04/03/2017] [Indexed: 11/25/2022] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive disease that usually affects elderly people. It has a poor prognosis and there are limited therapies. Since epigenetic alterations are associated with IPF, histone deacetylase (HDAC) inhibitors offer a novel therapeutic strategy to address the unmet medical need. This study investigated the potential of romidepsin, an FDA-approved HDAC inhibitor, as an anti-fibrotic treatment and evaluated biomarkers of target engagement that may have utility in future clinical trials. The anti-fibrotic effects of romidepsin were evaluated both in vitro and in vivo together with any harmful effect on alveolar type II cells (ATII). Bronchoalveolar lavage fluid (BALF) from IPF or control donors was analyzed for the presence of lysyl oxidase (LOX). In parallel with an increase in histone acetylation, romidepsin potently inhibited fibroblast proliferation, myofibroblast differentiation and LOX expression. ATII cell numbers and their lamellar bodies were unaffected. In vivo, romidepsin inhibited bleomycin-induced pulmonary fibrosis in association with suppression of LOX expression. LOX was significantly elevated in BALF of IPF patients compared to controls. These data show the anti-fibrotic effects of romidepsin, supporting its potential use as novel treatment for IPF with LOX as a companion biomarker for evaluation of early on-target effects.
Collapse
Affiliation(s)
- Franco Conforti
- The Brooke Laboratory, Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.,NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK
| | - Elizabeth R Davies
- The Brooke Laboratory, Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.,NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK
| | - Claire J Calderwood
- The Brooke Laboratory, Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK
| | - Thomas H Thatcher
- Department of Medicine/Pulmonary & Critical Care, University of Rochester, Rochester, NY, USA
| | - Mark G Jones
- The Brooke Laboratory, Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.,NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK
| | - David E Smart
- The Brooke Laboratory, Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.,NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK
| | - Sumeet Mahajan
- Institute for Life Sciences, University of Southampton, Highfield, UK
| | | | - Tom Havelock
- NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK.,University Hospital Southampton, Southampton, UK
| | - Toby M Maher
- NIHR Respiratory Biomedical Research Unit, Royal Brompton Hospital, London, UK.,National Heart & Lung Institute, Faculty of Medicine, Imperial College, London, UK
| | - Philip L Molyneaux
- NIHR Respiratory Biomedical Research Unit, Royal Brompton Hospital, London, UK.,National Heart & Lung Institute, Faculty of Medicine, Imperial College, London, UK
| | - Andrew J Thorley
- National Heart & Lung Institute, Faculty of Medicine, Imperial College, London, UK
| | - Teresa D Tetley
- National Heart & Lung Institute, Faculty of Medicine, Imperial College, London, UK
| | - Jane A Warner
- The Brooke Laboratory, Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.,NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK.,Institute for Life Sciences, University of Southampton, Highfield, UK
| | - Graham Packham
- Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK
| | - A Ganesan
- School of Pharmacy, University of East Anglia, Norwich, UK
| | - Paul J Skipp
- Institute for Life Sciences, University of Southampton, Highfield, UK
| | | | - Luca Richeldi
- The Brooke Laboratory, Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.,NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK.,University Hospital Southampton, Southampton, UK
| | - Patricia J Sime
- Department of Medicine/Pulmonary & Critical Care, University of Rochester, Rochester, NY, USA
| | - Katherine M A O'Reilly
- NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK.,Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.,School of Medicine and Medical Science, University College, Dublin, Ireland
| | - Donna E Davies
- The Brooke Laboratory, Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.,NIHR Respiratory Biomedical Research Unit, University Hospital Southampton, Southampton, UK.,Institute for Life Sciences, University of Southampton, Highfield, UK
| |
Collapse
|
2
|
Kumari S, Panda TK, Pradhan T. Lysyl Oxidase: Its Diversity in Health and Diseases. Indian J Clin Biochem 2017; 32:134-141. [PMID: 28428687 PMCID: PMC5382067 DOI: 10.1007/s12291-016-0576-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Accepted: 05/06/2016] [Indexed: 01/27/2023]
Abstract
The mechanical properties of extracellular matrix (ECM) and connective tissues is largely dependent on the collagen and elastin structure. Lysyl oxidase (LOX) plays a critical role in the formation and repair of the ECM by oxidizing lysine residues in elastin and collagen, thereby initiating the formation of covalent cross linkages which stabilize these fibrous proteins. Due to its multiple functions both extracellularly and intracellularly, lysyl oxidase is involved in several processes in the tumorigenic pathway, in many different cancer types and stages. Alteration in LOX activity is implicated in many diseases and disorders including inflammation and inflammatory diseases, fibrosis of distinct organs and fibrotic disorders, cancer promotion and progression. There are only sparse reports of mutations or epigenetic alterations in the LOX gene. This review provides the recent clinical developments in the molecular mechanisms and pathologic process, pointing out LOX as a potential therapeutic target in translational medicine.
Collapse
Affiliation(s)
- Suchitra Kumari
- Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India
| | | | | |
Collapse
|
3
|
Ward ST, Weston CJ, Hepburn E, Damery S, Hejmadi RK, Morton DG, Middleton G, Ismail T, Adams DH. Evaluation of serum lysyl oxidase as a blood test for colorectal cancer. Eur J Surg Oncol 2013; 40:731-8. [PMID: 24246612 DOI: 10.1016/j.ejso.2013.10.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2013] [Revised: 10/21/2013] [Accepted: 10/26/2013] [Indexed: 01/03/2023] Open
Abstract
AIMS Lysyl oxidase (LOX) expression is elevated in colorectal cancer (CRC) tissue and associated with disease progression. A blood test may form a more acceptable diagnostic test for CRC although LOX has not previously been measured in the serum. We therefore sought to determine the clinical usefulness of a serum LOX test for CRC in a symptomatic population. METHODS Adult patients referred to a hospital colorectal clinic with bowel symptoms completed a questionnaire and provided a blood sample for serum LOX measurement. Associations between presenting symptoms, serum LOX concentrations and outcomes of investigations were tested by univariate and multivariate analyses to determine if serum LOX was clinically useful in the prediction of CRC. LOX expression in CRC and adjacent colon biopsies was evaluated by ELISA and immunohistochemistry. RESULTS Thirty-one cases of colorectal cancer and 16 high-risk polyps were identified from a total of 962 participants. There was no association between serum LOX concentration and the presence of CRC, high-risk polyps or cancers at any site. LOX expression was significantly increased in CRC tissue compared to adjacent colon. CONCLUSION Despite overexpression of LOX in CRC tissue, elevated serum levels could not be demonstrated. Serum LOX measurement is therefore not a clinically useful test for CRC.
Collapse
Affiliation(s)
- S T Ward
- NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham, Edgbaston, Birmingham B15 2WB, UK.
| | - C J Weston
- NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham B15 2TT, UK
| | - E Hepburn
- NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham, Edgbaston, Birmingham B15 2WB, UK
| | - S Damery
- NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham B15 2TT, UK
| | - R K Hejmadi
- University Hospitals Birmingham, Edgbaston, Birmingham B15 2WB, UK
| | - D G Morton
- NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham, Edgbaston, Birmingham B15 2WB, UK
| | - G Middleton
- NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham B15 2TT, UK; University Hospitals Birmingham, Edgbaston, Birmingham B15 2WB, UK
| | - T Ismail
- University Hospitals Birmingham, Edgbaston, Birmingham B15 2WB, UK
| | - D H Adams
- NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham B15 2TT, UK
| |
Collapse
|
6
|
Murawaki Y, Kusakabe Y, Hirayama C. Serum lysyl oxidase activity in chronic liver disease in comparison with serum levels of prolyl hydroxylase and laminin. Hepatology 1991. [PMID: 1683640 DOI: 10.1002/hep.1840140635] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Lysyl oxidase was partially purified from serum by a diethylaminoethyl batch procedure in the presence of 6 mol/L urea and dialyzed against 3 mol/L KSCN. Using this method, we determined serum lysyl oxidase activity in 52 patients with liver disease and in 14 healthy controls, and we examined usefulness of serum lysyl oxidase in assessing liver fibrogenesis. For this purpose, serum lysyl oxidase activity in chronic liver disease was compared with serum levels of prolyl hydroxylase and laminin P1. As compared with controls, serum lysyl oxidase activity increased 1.6-fold in chronic persistent hepatitis, 4.4-fold in chronic active hepatitis and 11.8-fold in cirrhosis, indicating an increase in concert with the development of liver fibrosis. In hepatocellular carcinoma, the serum activity, although significantly increased, was lower than that in cirrhosis. Serum prolyl hydroxylase was significantly increased in chronic active hepatitis, in liver cirrhosis and in hepatocellular carcinoma. Serum laminin P1 was significantly increased in chronic active hepatitis, in cirrhosis and in hepatocellular carcinoma. Serum lysyl oxidase activity did not correlate significantly with serum levels of prolyl hydroxylase and laminin P1 in any subject or in any subgroup. The magnitude of the increase and the abnormal percentage of serum lysyl oxidase activity were larger than those for serum prolyl hydroxylase and laminin P1. These results suggest that serum lysyl oxidase activity is a more sensitive indicator of liver fibrosis than serum prolyl hydroxylase and laminin P1.
Collapse
Affiliation(s)
- Y Murawaki
- Second Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan
| | | | | |
Collapse
|